Functional Evaluation of Two Types of Totally Implanted Venous Ports

Sponsor
Universitaire Ziekenhuizen Leuven (Other)
Overall Status
Completed
CT.gov ID
NCT00484848
Collaborator
RITA Medical Systems (Industry), B. Braun Medical SA (Industry)
200
1
5.9
33.6

Study Details

Study Description

Brief Summary

Totally implanted venous access ports allow a safe delivery of medication, mainly chemotherapy, but are also used for blood sampling. This last procedure is not always successful, as it appeared from a nurse's survey in different hospitals in Flanders, including the University Hospitals in Leuven, Belgium. In 3 to 29 percent of the attempts, blood withdrawal is impaired or not possible, as an intermittent or permanent fact. This is in line with international literature data where difficulty in blood draw was noted in 6 to 26% of port accessions. Partial or total occlusion leads to discomfort for the patient, delay in therapy, higher costs and extra nursing time.

A new port system with a tangential outlet (Vortex port) was designed and according to the manufacturer, this shape will allow to cleanse the entire reservoir of the port more efficiently and avoid the formation of precipitates of medication or blood that could lead to an obstruction of the device. These precipitates are also regarded as a potential risk factor for infection.

However, only one previously published small randomised study addressed the value of the Vortex port when compared to conventional access devices: Stevens et al. were able to show a reduction in obstruction incidence from 26% to 7% with the use of the Vortex port. The incidence of blood withdrawal problems in our experience with conventional ports in University hospitals Leuven was 8% thus lower than that reported by Stevens, but this remains the most frequent problem faced by care providers and patients.

With this study, the investigators aim to compare the performance of the tangential outlet ports and that of a "conventional" port in order to assess an eventual functional difference.

Condition or Disease Intervention/Treatment Phase
  • Device: Vortex port and Celsite port
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Care Provider)
Primary Purpose:
Supportive Care
Official Title:
Functional Evaluation of Conventional Venous Access Port (Celsite®) Versus Venous Access Port With Tangential Outlet (Vortex®) : a Prospective Randomized Pilot Study
Study Start Date :
Sep 1, 2004
Actual Primary Completion Date :
Dec 1, 2004
Actual Study Completion Date :
Mar 1, 2005

Outcome Measures

Primary Outcome Measures

  1. Evaluation of the difference in difficulty in blood drawing between the 2 types of ports when accessing the port under identical maintenance procedure according to the guidelines in the University Hospitals Leuven. [up to a maximum of 6 months after insertion]

  2. Evaluation of the difference in one-way or bidirectional occlusion incidence between these 2 types of ports, when accessing the port under identical maintenance procedure according to the guidelines in the University Hospitals Leuven. [up to a maximum of 6 months after insertion]

  3. Evaluation of the difference in filling time for blood sampling between these 2 types of ports when using a standard 10 ml vacuum blood tube and a 19 G Gripper® needle. [immediately after insertion and up to a maximum of 6 months afterwards]

Secondary Outcome Measures

  1. Evaluation of the ease of use (ease of access) between these 2 types of ports when accessing the port. [up to a maximum of 6 months after insertion]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • request of a standard size totally implanted venous port

  • patent superior vena cava

  • normal clotting tests (PT>40% and platelet count >40000/mm3)

Exclusion Criteria:
  • unable to provide written informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospitals Leuven Leuven Belgium 3000

Sponsors and Collaborators

  • Universitaire Ziekenhuizen Leuven
  • RITA Medical Systems
  • B. Braun Medical SA

Investigators

  • Principal Investigator: Marguerite Stas, MD PhD, KU Leuven

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00484848
Other Study ID Numbers:
  • SM007
First Posted:
Jun 11, 2007
Last Update Posted:
Jan 26, 2009
Last Verified:
Jan 1, 2009

Study Results

No Results Posted as of Jan 26, 2009